JP/ZH: Currently, only the Luminex LTG section and the Service & Support pages regarding Luminex LTG are available in Japanese/Chinese.
13/10/26 - 13:00
Diasorin obtained FDA approval for Human Parvovirus B19 IgM and IgG on the Liaison XL (334.34 KB)
02/10/26 - 14:22
Margherita Sacerdoti appointed Investor Relations & ESG Senior Director at Diasorin (151.77 KB)
31/07/26 - 12:50
Revenue and EBITDA Supported by Strong Q2 Growth in the First Half of the Year. 2026 Guidance Confirmed. (277.39 KB)
19/06/26 - 15:45
Diasorin Announces FDA 510(K) Clearance and CLIA Waiver for the LIAISON NES Group A Streptococcus (GAS) Assay (174.02 KB)
20/05/26 - 11:16
Diasorin Board of Directors approves the 2026-2030 Business Plan (246.32 KB)
19/05/26 - 19:23
Diasorin Receives 510(K) Clearance for Fully Customizable LIAISON PLEX Gastrointestinal Flex Assay (179.61 KB)
08/05/26 - 17:54
Revenues and EBITDA in line with the expected quarterly revenue trend and impacted by a weak flu season. 2026 Guidance confirmed (256.38 KB)
04/05/26 - 17:45
Diasorin Strengthens its Leadership of Immuno Division with the Appointment of Gabriele Allegri as President (158.42 KB)
29/04/26 - 15:52
Shareholders' Meeting 2026 (166.06 KB)
07/04/26 - 10:05
Communication on total amount of voting rights (7 April 2026) (225.44 KB)
25/03/26 - 12:04
Publication of the document for the Ordinary Shareholders' Meeting scheduled on April 29, 2026 (181.97 KB)
20/03/26 - 17:44
Revenues and EBITDA growth in line with FY 2025 Guidance. Proposed ordinary dividend per share of €1.30, +8.3% vs 2024 (349.08 KB)
19/03/26 - 9:47
Diasorin signs strategic distribution agreement with McKesson Medical Surgical to expand access for the LIAISON NES molecular point‑of‑care platform (234.16 KB)
24/02/26 - 7:06
Diasorin introduces next-generation LIAISON QuantiFERON-TB Gold Plus II assay for the U.S. in partnership with QIAGEN (154.8 KB)
03/02/26 - 12:13
Diasorin submits LIAISON NES Group A Strep molecular test to the U.S. FDA for 510(k) Clearance and CLIA Waiver (130.94 KB)
29/01/26 - 7:03
Diasorin has been granted De novo authorization in the U.S. for the First Fully Automated Laboratory Test for Hepatitis Delta Virus (HDV) on the LIAISON XL (128.56 KB)
27/01/26 - 16:05
The Shareholders' meeting authorized the purchase of treasury shares, approved the amendment of art. 5 of the articles of association and authorized the cancellation of treasury shares. The Board approved the launch of the buyback plan. (120.91 KB)
26/01/26 - 7:09
Diasorin signs exclusive distribution agreement for the LIAISON NES® molecular point‑of‑care platform and the Flu A/B, RSV & Covid‑19 panel (131.63 KB)
23/01/26 - 17:49
Succession in the role of Group Chief Financial Officer of Diasorin. Alberto Donati appointed new Group Chief Financial Officer. (108.99 KB)
22/12/10 - 1:00
2011 Financial calendar (180.28 KB)
20/12/10 - 1:00
Dividend may be distributed in June (445.78 KB)
02/12/10 - 1:00
Comment on position Paper on Vitamin D (53.46 KB)
24/11/10 - 1:00
Change in share capital (46.85 KB)
18/11/10 - 1:00
Financial instruments to employees (48.33 KB)
05/11/10 - 1:00
The BoD approves Q3'10 results (414.16 KB)
02/11/10 - 1:00
Change in share capital (313.61 KB)
08/10/10 - 2:00
2010 Financial calendar update (174.1 KB)
30/09/10 - 2:00
Change in share capital (5.25 KB)
24/09/10 - 2:00
Financial instruments to employees (48.81 KB)
16/09/10 - 2:00
Stock options exercised by key managers (195.67 KB)
02/09/10 - 2:00
Financial instruments to employees (24.27 KB)
06/08/10 - 2:00
The BoD approves H1'10 results (287.11 KB)
07/07/10 - 2:00
Agreement with Meridian Inc. (182.7 KB)
06/07/10 - 2:00
2010 Financial calendar update (174.1 KB)
02/07/10 - 2:00
Financial instruments to employees (24.37 KB)
01/06/10 - 2:00
Acquisition of MUREX product line (102.6 KB)
14/05/10 - 2:00
The BoD approves Q1'10 results (254.05 KB)
27/04/10 - 2:00
Approval of statutory financial statements (182.99 KB)
20/04/10 - 2:00
2010 Financial calendar update (168.23 KB)
14/04/10 - 2:00
Postponement of the term for lists of members of the Board of Auditors (40.34 KB)
09/04/10 - 2:00
China approves new prenatal screening product line on LIAISON (141.08 KB)
02/04/10 - 2:00
Financial instruments to employees (27.79 KB)
22/03/10 - 1:00
The BoD approves FY 2009 results (306.02 KB)
10/03/10 - 1:00
Acquisition of MUREX product line (45.5 KB)
01/03/10 - 1:00
2010 Financial calendar update (192.49 KB)
12/02/10 - 1:00
The BoD approves Q4'09 results (213.8 KB)
18/01/10 - 1:00